A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

Inclusion Criteria:

• 12 years ≤ age ≤ 18 years
• With atopic dermatis
• Voluntarily sign the informed consent form

Exclusion Criteria:

• Weight < 30 kg
• Major surgery planed during the study